Home›Stock Screener›Nectar Lifesciences›Quarterly Results

Nectar Lifesciences Quarterly Results

Latest Quarter Net Profit
₹3 Cr
QSept 2026
Quarterly Results

Nectar Lifesciences quarterly results. In Sept 2026, Nectar Lifesciences (NECLIFE) reported revenue ₹14 Cr and net profit ₹3 Cr. View Nectar Lifesciences 52-week for the annual high/low range and current price position.

NECLIFE Quarterly Results — Revenue, Profit & EPS Highlights

Nectar Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Nectar Lifesciences share price chart.

  • Revenue of ₹14 Cr in Sept 2026 (+133.3% vs Mar 2026)
  • Net Profit of ₹3 Cr in Sept 2026 (+104.4% vs Mar 2026, +101.7% vs Sept 2025)
  • EBITDA of ₹7 Cr in Sept 2026 (+108.4% vs Mar 2026)
  • Operating Margin of -75200.0% in Sept 2026
  • Earnings Per Share of ₹0.14 in Sept 2026 (+104.1% vs Mar 2026)

Nectar Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS

NECLIFE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2026 Mar 2026 Jun 2026 Sept 2025 Mar 2025 QoQ YoY
Revenue (₹ Cr) 14 6 3 0 0 133.3% -
Net Profit (₹ Cr) 3 -68 -15 -176 -130 - -
EBITDA (₹ Cr) 7 -83 -25 -176 -130 - -
EPS (₹) 0.14 -3.38 -0.79 -7.85 -5.80 - -
Operating Margin (%) -75200.0% 0.0% -277000.0% 0.0% 0.0% - -

NECLIFE Share Price Trend — 1-Year Movement Across Quarterly Results

Nectar Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore NECLIFE share price charts to track price trends across different timeframes.

Profitability Ratios

Profit Margin 21.4%
EBITDA Margin 50.0%
Operating Margin -75200.0%
ROE (Annual) 2.1%

Balance Sheet Highlights

Total Assets ₹622 Cr
Total Equity ₹582 Cr
Current Assets ₹ Cr
Current Liabilities ₹13 Cr

Cash Flow Analysis

Operating Cash Flow ₹-349 Cr
Investing Cash Flow ₹1,208 Cr
Financing Cash Flow ₹-767 Cr
Net Cash Flow ₹93 Cr

Current Market Data

Current Price ₹9.81
Exchange NSE
Last Updated Nov 20, 2026

NECLIFE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Nectar Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2026
₹451,074.97 Cr 1884.9 16,617 1,995 +10.6% - 12.0% 227.1
Divis Laboratories
Sept 2026
₹294,139.19 Cr 11180.5 3,770 1,127 +26.3% - 29.9% 263.1
Torrent Pharmaceuti…
Mar 2026
₹188,719.51 Cr 4689.5 4,111 364 +27.7% +42.2% 8.9% 407.4
Apollo Hospitals
Sept 2026
₹132,281.88 Cr 9200.0 7,673 660 +15.2% - 8.6% 209.9
Laurus Labs
Sept 2026
₹125,946.78 Cr 2294.6 2,219 436 +21.7% - 19.6% 280.9
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores